SCYX vs. MNOV, MURA, KRON, CALC, VHAQ, ANVS, YS, KZR, CARM, and ASMB
Should you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include MediciNova (MNOV), Mural Oncology (MURA), Kronos Bio (KRON), CalciMedica (CALC), Viveon Health Acquisition (VHAQ), Annovis Bio (ANVS), YS Biopharma (YS), Kezar Life Sciences (KZR), Carisma Therapeutics (CARM), and Assembly Biosciences (ASMB). These companies are all part of the "pharmaceutical preparations" industry.
SCYNEXIS (NASDAQ:SCYX) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.
54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 4.4% of SCYNEXIS shares are held by company insiders. Comparatively, 16.9% of MediciNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, MediciNova had 3 more articles in the media than SCYNEXIS. MarketBeat recorded 4 mentions for MediciNova and 1 mentions for SCYNEXIS. MediciNova's average media sentiment score of 0.80 beat SCYNEXIS's score of 0.00 indicating that MediciNova is being referred to more favorably in the news media.
SCYNEXIS has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500.
SCYNEXIS received 296 more outperform votes than MediciNova when rated by MarketBeat users. Likewise, 70.24% of users gave SCYNEXIS an outperform vote while only 52.25% of users gave MediciNova an outperform vote.
SCYNEXIS has a net margin of 47.84% compared to MediciNova's net margin of 0.00%. SCYNEXIS's return on equity of 156.27% beat MediciNova's return on equity.
SCYNEXIS has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.
SCYNEXIS presently has a consensus target price of $15.00, suggesting a potential upside of 767.05%. Given SCYNEXIS's higher probable upside, equities analysts clearly believe SCYNEXIS is more favorable than MediciNova.
Summary
SCYNEXIS beats MediciNova on 13 of the 17 factors compared between the two stocks.
Get SCYNEXIS News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SCYNEXIS Competitors List
Related Companies and Tools
